Vivos Therapeutics (NASDAQ:VVOS) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Vivos Therapeutics (NASDAQ:VVOS) posted its quarterly earnings results on Wednesday. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04, FiscalAI reports. The firm had revenue of $6.78 million for the quarter, compared to the consensus estimate of $4.49 million. Vivos Therapeutics had a negative net margin of 99.49% and a negative return on equity of 232.76%.

Vivos Therapeutics Price Performance

VVOS traded down $0.00 during midday trading on Thursday, hitting $2.36. The company had a trading volume of 54,054 shares, compared to its average volume of 358,803. Vivos Therapeutics has a twelve month low of $1.98 and a twelve month high of $7.95. The company has a market capitalization of $17.67 million, a PE ratio of -1.44 and a beta of 6.87. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.05 and a current ratio of 1.05. The firm’s 50-day simple moving average is $2.94 and its 200-day simple moving average is $3.51.

Analysts Set New Price Targets

VVOS has been the topic of several recent research reports. HC Wainwright initiated coverage on shares of Vivos Therapeutics in a research report on Monday. They set a “buy” rating and a $7.00 target price on the stock. Wall Street Zen downgraded Vivos Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, October 8th. Zacks Research downgraded shares of Vivos Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 31st. Finally, Ascendiant Capital Markets upped their target price on shares of Vivos Therapeutics from $6.20 to $6.50 and gave the stock a “buy” rating in a report on Tuesday, September 9th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $5.25.

Institutional Trading of Vivos Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Connective Capital Management LLC acquired a new position in Vivos Therapeutics during the 3rd quarter worth $620,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Vivos Therapeutics during the second quarter worth $220,000. Finally, XTX Topco Ltd acquired a new position in shares of Vivos Therapeutics during the second quarter valued at $65,000. Institutional investors and hedge funds own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.